Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2010-07-01
2011-11-15
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S032000, C435S261000
Reexamination Certificate
active
08058025
ABSTRACT:
An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined.
REFERENCES:
patent: 4423145 (1983-12-01), Stampfer et al.
patent: 4559299 (1985-12-01), Rotman
patent: 4668618 (1987-05-01), Thornthwaite
patent: 4816395 (1989-03-01), Hancock et al.
patent: 4937187 (1990-06-01), Rotman
patent: 4996145 (1991-02-01), Weisenthal
patent: 5242806 (1993-09-01), Yen-Maguire et al.
patent: 5270172 (1993-12-01), Morgan
patent: 5403574 (1995-04-01), Piwnica-Worms
patent: 5443950 (1995-08-01), Naughton et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5705270 (1998-01-01), Soon-Shiong et al.
patent: 5728541 (1998-03-01), Kornblith
patent: 5789158 (1998-08-01), Knowles et al.
patent: 5874218 (1999-02-01), Drolet et al.
patent: 5888765 (1999-03-01), Patterson et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5972639 (1999-10-01), Parandoosh
patent: 6008007 (1999-12-01), Fruehauf et al.
patent: 6020473 (2000-02-01), Keyt et al.
patent: 6069134 (2000-05-01), Roth et al.
patent: 6111092 (2000-08-01), Williamson
patent: 6261795 (2001-07-01), Fruehauf et al.
patent: 6274576 (2001-08-01), Grimley et al.
patent: 6303324 (2001-10-01), Fruehauf
patent: 6335170 (2002-01-01), Orntoft
patent: 6416967 (2002-07-01), Kornblith
patent: 6511806 (2003-01-01), Fruehauf et al.
patent: 6664062 (2003-12-01), Stanton, Jr.
patent: 6887680 (2005-05-01), Kornblith
patent: 6900017 (2005-05-01), Sharma et al.
patent: 6900027 (2005-05-01), Kornblith
patent: 6933129 (2005-08-01), Kornblith
patent: 7112415 (2006-09-01), Kornblith
patent: 7314731 (2008-01-01), Kornblith
patent: 7501260 (2009-03-01), Kornblith
patent: 7563593 (2009-07-01), Kornblith
patent: 7575868 (2009-08-01), Kornblith et al.
patent: 7678552 (2010-03-01), Kornblith
patent: 7771963 (2010-08-01), Kornblith
patent: 7829288 (2010-11-01), Kornblith et al.
patent: 2001/0051353 (2001-12-01), Kornblith
patent: 2002/0168679 (2002-11-01), Naus et al.
patent: 2002/0192638 (2002-12-01), Kornblith
patent: 2003/0096290 (2003-05-01), Fruehauf et al.
patent: 2004/0023375 (2004-02-01), Kornblith et al.
patent: 2004/0072722 (2004-04-01), Kornblith et al.
patent: 2004/0086888 (2004-05-01), Kornblith et al.
patent: 2005/0202410 (2005-09-01), Kornblith
patent: 2007/0037136 (2007-02-01), Kornblith
patent: 2007/0059821 (2007-03-01), Kornblith et al.
patent: WO 96/10742 (1996-04-01), None
patent: WO 98/02038 (1998-01-01), None
patent: WO 02/33117 (2002-04-01), None
patent: WO 2004/015065 (2004-02-01), None
patent: WO 2004/035833 (2004-04-01), None
PL Kornblith et al., “Response variability of human brain tumors to AZQ in tissue culture,” Journal of Neuro-Onocology, 1986, pp. 49-54, vol. 4, Martinus Nijhoff Publishers, Boston.
RS Weinstein et al., “Ultrastructure of a cloned astrocytoma in tissue culture,” Cancer, 1971, pp. 1174-1181, vol. 27.
PMcL Black et al., “Ultrastructural and electrophysiological features of meningioma whorls in tissue culture,” Acta Neuropathol (Berl), 1979, vol. 46, pp. 33-38.
RM Scott et al., “Invasiveness in tissue culture: A technique for study of gliomas,” Surg Forum, 1978, pp. 531-533, vol. 29.
T. Liszczak et al., “Morphological, biochemical, ultrastructural, tissue culture and clinical observations of typical and aggressive craniopharyngiomas,” Acta Neuropathol (Berl), 1978, pp. 191-203, vol. 43.
PL Kornblith et al., “Growth-inhibitory effects of diphenylhydantoin on human brain tumor cells in culture,” Neurosurgery, 1978, pp. 122-127, vol. 2.
RR Weichselbaum et al., “Characterization and radiobiologic parameters of medulloblastoma in vitro,” Cancer, 1977, pp. 1087-1096, vol. 40.
RL Martuza et al., “Characteristics of human optic gliomas in tissue culture,” J. Neurosurg, 1977, pp. 78-84, vol. 46.
MA Oberc-Greenwood, et al., “Ultrastructural features of the lymphocyte-stimulated halos produced by human glioma-derived derived cells in vitro,” Journal of Neuro-Oncology, 1986, pp. 387-396, vol. 3.
BH Smith et al., “Membrane and cytoplasmic changes in 1,3-bis (2-chloroethy 1)- 1—nitrosourea (BCNU)-sensitive and resistant human malignant glioma-derived cell lines,” Journal of Neuro-Oncology, 1983, pp. 237-248, vol. 1.
GA Curt et al., “Phase Il and pharmacokinetic study of aziridinyl-benzoquinone (2,5-diaziridinyl-3, 6-bis(carboethoxyamino)-1,4 benzoquinone, diaziquone, NSC 182986) in high grade gliomas,” Cancer Research, 1983, pp. 6102-6105, vol. 43, Issue 12 pt I.
N Shitara et al., “Flowcytometric and cytogenetic analysis of human cultured cell lines derived from high- and low-grade astrocytomas,” Acta Neuropathol (Berl), 1983, pp. 40-48, vol. 60.
MK Gumerlock et al., “Chemical differentiation of cultured human glioma cells: Morphologic and immunologic effects,” Surgical Forum, 1981, pp. 475-477, vol. XXXII.
PL Kornblith et al., “Growth-inhibitory effect of diphenylhydantoin on murine astrocytomas,” Neurosurgery, 1979, pp. 259-263, vol. 5.
MC Trachtenberg et al., “Biophysical properties of cultured human glial cells,” Brain Research, 1972, pp. 279-298, vol. 38.
J. Lightbody et al., “Biochemically differentiated clonal human glial cells in tissue culture,” J. Neurobiology, 1970, pp. 411-417, vol. 1, No. 4.
PMcL Black et al., “Biophysical properties of human astrocytic brain tumor cells in cell nature,” Journal of Cellular Physiology, 1980, pp. 565-570, vol. 105.
TM Liszczak et al., “Ultrastructure of human endometrial epithelium in monolayer culture with and without steroid hormones,” In Vitro, 1977, pp. 344-356, vol. 13, No. 6.
TM Liszczak et al., “Procedure for the embedment and ultrastructural visualization of cells cultured on plastic microtest plates,” Journal of Immunological Methods, 1977, pp. 131-134, vol. 15.
RM Stewart et al., “Glutamate accumulation by human gliomas and meningiomas in tissue culture,” Brain Research, 1976, pp. 441-452, vol. 118.
PL Kornblith et al., “The future of therapy for glioblastoma,” Surg Neurol, 1993, pp. 538-543, vol. 39.
PL Kornblith, “Management of malignant gliomas,” Neurosurgery Quarterly, 1991, pp. 97-110, vol. I, Issue 2.
PL Kornblith et al., “Chemotherapy for malignant gliomas,” Journal of Neurosurgery, 1988, pp. 1-17, vol. 68, Issue 1.
PE McKeever et al., “Products of cells cultured from gliomas: VI. Immunofluorescent, morphometric, and ultrastructural characterization of two different cell types growing from explants of human gliomas,” American Journal of Pathology, 1987, pp. 358-372, vol. 127, Issue 2.
PMcL Black et al., “Immunological, biological, ultrastructural, and electrophysiological characteristics of a human glioblastoma-derived cell culture line,” J. Neurosurg., 1982, pp. 62-72, vol. 56.
PL Kornblith, “The role of cytotoxic chemotherapy in the treatment of malignant brain tumors,” Surg Neurol, 1995, pp. 551-552, vol. 44.
WC Welch et al., “Morphologic immunologic, biochemical and cytogenetic characteristics of the human glioblastoma-derived cell line, SNB-19,” Journal of the Society for In Vitro Biology, 1995, pp. 610-616, vol. 31.
E Sariban et al., “DNA crosslinking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin and diazi
Cooley LLP
Gitomer Ralph
Precision Therapeutics, Inc.
LandOfFree
Methods for determining efficacy of chemotherapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for determining efficacy of chemotherapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining efficacy of chemotherapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4294515